SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A. DeFronzo
May 1, 2016; 39:717-725
Cardiovascular Disease and Diabetes
Diabetes Care: Most-Read Full-Text Articles


SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study was first posted on October 31, 2016 at 1:16 am.
©2013 “DIABETICS DIET“. Use of this feed is for personal non-commercial use only. If you are not reading this article in your feed reader, then the site is guilty of copyright infringement. Please contact me at jmagcase@gmail.com

Reblogged 6 months ago from diabeticscareguide.com

Published by

Amrita Wellness Medicine Clinic

Alina Porojan has been working as a natural medicine practitioner for the past twelve years, constantly educating herself and deepening her knowledge and clinical experience. Alina believes that health and healing is inherent to each of us, and sees her role as re-connecting us to our already existing potential for optimal health and wellness.